FIELD: medicine.
SUBSTANCE: invention refers to drugs, and concerns an application of an LXR agonist for preparing a drug effective for treatment and/or prevention of type I diabetes and a method of increasing primary pancreatic islet viability ex vivo wherein said pancreatic islets contact with the LXR agonist.
EFFECT: extended range of products for type I diabetes treatment.
13 cl, 8 dwg, 8 ex
Authors
Dates
2011-04-27—Published
2006-05-10—Filed